 Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the companys selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis RRMS. The study achieved all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the study met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active CUA magnetic resonance imaging MRI lesions up to week 24 in patients receiving 45mg of IMU-838 once daily, by 62 p0.0002, as compared to placebo. The study also met its key secondary endpoint, showing a statistically significant reduction in the cumulative number of CUA MRI lesions for the 30mg once daily dose, by 70 p0.0001, as compared to placebo. 